CRISPR Therapeutics remains a standout in the gene-editing sector as the only firm with an approved product, yet shares trade significantly below analyst targets amid a slow commercial ramp for CASGEVY.
CRSP is the primary subject, trading 48% below consensus target with a Street-high $110 target from Piper Sandler and CASGEVY revenue growing 151% YoY.
BEAM has a consensus target implying 101% upside with 13 of 15 analysts Buy-rated, but the article does not provide a specific recommendation.
NTLA is mentioned as a peer with 89% implied upside to consensus target, but shares are down 26.48% over the past year.
Vertex is CRISPR's partner on CASGEVY, with partner-reported revenue surging 151% YoY, but the article does not provide a specific view on VRTX stock.
EDIT shows the largest implied upside on paper but has 2 Strong Sells against 6 Buys, indicating skepticism.
The S&P 500 is mentioned as a benchmark, up 13.41% YTD and 15.98% over the past year.
CRISPR Therapeutics (CRSP) currently trades at a 48% discount to the Wall Street consensus price target of $87.56, despite the successful commercialization of its gene therapy, CASGEVY. While the company faces market skepticism and volatility, its $2.56 billion cash position and unique status as the only peer with an approved product provide a distinct competitive advantage.
CRISPR Therapeutics is the only company in its peer group, which includes Intellia, Beam, and Editas, that has an FDA-approved, revenue-generating gene therapy on the market.
The primary catalysts include the continued commercial ramp of CASGEVY, potential pediatric label expansion for the therapy, and upcoming clinical data readouts from its wholly-owned pipeline, including CTX310.